Investors & Media

What’s new.

Press releases

Press releases.

May 26th 2025

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 15th 2025

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 5th 2025

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

more

Investor updates

Investor updates.

April 23rd 2025

Investor Update - April 2025

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

more

Analyst reports

Analyst reports.

May 16th 2025

Maxim - Positive Response Data from INSIGHT-003 in 1L NSCLC; Bodes Well for Ongoing P3 Pivotal TACTI-004 Study - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

May 15th 2025

Baird - New IST Data for Triple Combo Further Supportive of Potential in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

May 15th 2025

CLSA - Insightful readout; Strong TPS-below-50% result highlights Keytruda expansion opportunity; Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

more